313 related articles for article (PubMed ID: 10092645)
1. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
[TBL] [Abstract][Full Text] [Related]
2. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
[TBL] [Abstract][Full Text] [Related]
4. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
van den Akker E; van Dijk TB; Schmidt U; Felida L; Beug H; Löwenberg B; von Lindern M
Biol Chem; 2004 May; 385(5):409-13. PubMed ID: 15196000
[TBL] [Abstract][Full Text] [Related]
5. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
Uckun FM; Tibbles H; Venkatachalam T; DuMez D; Erbeck D
Arzneimittelforschung; 2007; 57(1):31-46. PubMed ID: 17341007
[TBL] [Abstract][Full Text] [Related]
6. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
[TBL] [Abstract][Full Text] [Related]
7. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
Uckun F; Dibirdik I; Sarkissian A; Qazi S
Arzneimittelforschung; 2011; 61(4):252-9. PubMed ID: 21650085
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Cetkovic-Cvrlje M; Uckun FM
Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
[TBL] [Abstract][Full Text] [Related]
10. Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate.
DuMez D; Venkatachalam TK; Uckun FM
Arzneimittelforschung; 2007; 57(3):155-63. PubMed ID: 17469650
[TBL] [Abstract][Full Text] [Related]
11. Alpha-cyano-N-(2,5-dibromophenyl)-beta-hydroxybut-2-enamide.
Ghosh S; Uckun FM
Acta Crystallogr C; 1999 Aug; 55 ( Pt 8)():1364-5. PubMed ID: 10483706
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.
Tankiewicz-Kwedlo A; Hermanowicz JM; Domaniewski T; Pawlak K; Rusak M; Pryczynicz A; Surazynski A; Kaminski T; Kazberuk A; Pawlak D
Br J Pharmacol; 2018 Mar; 175(5):743-762. PubMed ID: 29160911
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase as a new therapeutic target.
Uckun FM; Tibbles HE; Vassilev AO
Anticancer Agents Med Chem; 2007 Nov; 7(6):624-32. PubMed ID: 18045057
[TBL] [Abstract][Full Text] [Related]
14. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F.
Tibbles HE; Samuel P; Erbeck D; Mahajan S; Uckun FM
Arzneimittelforschung; 2004; 54(6):330-9. PubMed ID: 15281619
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
16. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor.
Gilbert C; Levasseur S; Desaulniers P; Dusseault AA; Thibault N; Bourgoin SG; Naccache PH
J Immunol; 2003 May; 170(10):5235-43. PubMed ID: 12734372
[TBL] [Abstract][Full Text] [Related]
17. A dual function anti-leukemic agent with anti-thrombotic activity.
Tibbles H; Vassilev A; Uckun FM
Leuk Lymphoma; 2002 May; 43(5):1121-7. PubMed ID: 12148895
[TBL] [Abstract][Full Text] [Related]
18. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex.
Vassilev A; Ozer Z; Navara C; Mahajan S; Uckun FM
J Biol Chem; 1999 Jan; 274(3):1646-56. PubMed ID: 9880544
[TBL] [Abstract][Full Text] [Related]
19. The effects of Bruton tyrosine kinase inhibition on chemotaxis and superoxide generation in human neutrophils.
Broides A; Hadad N; Levy J; Levy R
J Clin Immunol; 2014 Jul; 34(5):555-60. PubMed ID: 24771458
[TBL] [Abstract][Full Text] [Related]
20. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]